From Early-Generation to Next-Generation Reversible BTK Inhibitors

Time: 10:10 am
day: Day Two


  • A number of BTK inhibitors have been developed over the years, but strikingly not all have demonstrated the same level of efficacy in clinical trials even within the same indication, partly reflecting the complexity of the regulation of this kinase and that not all inhibitors are created equal
  • In this presentation, we will discuss some of the lessons learned at Biogen in our efforts to target BTK and develop potent, selective and reversible inhibitors of this complex kinase